Targeting post-translational modifications to overcome glioblastoma therapy resistance: emerging strategies and natural compounds
- 1Graduate Program in Biochemistry, Department of Biochemistry, Federal University of Santa Catarina
- 2Graduate Program in Cell and Developmental Biology, Department of Cell Biology, Embryology and Genetics, Federal University of Santa Catarina
Abstract
Post-translational modifications (PTMs) regulate multiple mechanisms associated with glioblastoma (GBM) therapy resistance, which remains a major challenge in GBM treatment. Some resistance mechanisms involve genetic heterogeneity, glioblastoma stem cells, the tumor microenvironment, autophagy, metabolic reprogramming, vascular adaptation, and altered transcriptional regulation. By regulating protein activity, stability, localization, interactions, and signaling, PTMs can influence several of these processes and affect treatment response. This review examines the roles of phosphorylation, ubiquitination and ubiquitin-like modifications, acetylation, methylation, and glycosylation in resistance to temozolomide, radiotherapy, and targeted therapies. We further discuss emerging PTMs, including lactylation, succinylation, and UFMylation, for which evidence linking individual modifications to therapeutic resistance ranges from direct resistance mechanisms to effects primarily associated with GBM biology. PTM crosstalk is also discussed in the context of DNA repair, redox homeostasis, metabolism, glioblastoma stem cell maintenance, and therapy response. Finally, we examine pharmacological targeting of PTM-regulating enzymes and pathways and the effects of natural bioactive compounds on PTM-dependent mechanisms.
Related
- Role of histone post-translational modifications in preeclampsia: from pathogenesis to diagnostic and therapeutic strategies
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Translational Challenges and Strategies for Antibody Therapeutics in Glioblastoma.
- Tumor-associated macrophages beyond M1/M2 in NSCLC: spatially organized programs, therapy resistance, and translational targeting
- Peptides and Peptide Analogues Targeting Acetylcholinesterase-Associated Mechanisms in Alzheimer’s Disease and Dementias: Evidence Gaps, Design Strategies, and Translational Perspectives
BibTeX
@article{piermartiri2026targeting,
title = {{Targeting post-translational modifications to overcome glioblastoma therapy resistance: emerging strategies and natural compounds}},
author = {Tetsade Piermartiri and Ana Carolini Adriana da Matta and João Victor Krüger Pinto and Carla Inês Tasca and Cláudia Beatriz Nedel},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1984427},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1984427/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting post-translational modifications to overcome glioblastoma therapy resistance: emerging strategies and natural compounds
AU - Tetsade Piermartiri
AU - Ana Carolini Adriana da Matta
AU - João Victor Krüger Pinto
AU - Carla Inês Tasca
AU - Cláudia Beatriz Nedel
PY - 2026
DA - 2026/10/15
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1984427
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1984427/full
AB - Post-translational modifications (PTMs) regulate multiple mechanisms associated with glioblastoma (GBM) therapy resistance, which remains a major challenge in GBM treatment. Some resistance mechanisms involve genetic heterogeneity, glioblastoma stem cells, the tumor microenvironment, autophagy, metabolic reprogramming, vascular adaptation, and altered transcriptional regulation. By regulating protein activity, stability, localization, interactions, and signaling, PTMs can influence several of these processes and affect treatment response. This review examines the roles of phosphorylation, ubiquitination and ubiquitin-like modifications, acetylation, methylation, and glycosylation in resistance to temozolomide, radiotherapy, and targeted therapies. We further discuss emerging PTMs, including lactylation, succinylation, and UFMylation, for which evidence linking individual modifications to therapeutic resistance ranges from direct resistance mechanisms to effects primarily associated with GBM biology. PTM crosstalk is also discussed in the context of DNA repair, redox homeostasis, metabolism, glioblastoma stem cell maintenance, and therapy response. Finally, we examine pharmacological targeting of PTM-regulating enzymes and pathways and the effects of natural bioactive compounds on PTM-dependent mechanisms.
SN - 2234-943X
ER -